Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.43 |
| ▸ | ATP4A | P20648 | 7/20 | 0.41 |
| ▸ | ATP4B | P51164 | 7/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8403092 | 0.95 | GPR84 (0.49) | GPR84ATP4AATP4BHSD11B1SOAT1 | |
| SCHEMBL2090209 | 0.83 | PPARG (0.36) | GPR84ATP4AATP4BMAPTALDH1A1 | |
| SCHEMBL23072120 | 0.82 | ALDH1A1 (0.50) | ATP4AATP4BMAPTALDH1A1 | |
| SCHEMBL2090690 | 0.81 | PPARG (0.35) | GPR84ATP4AATP4BMAPTALDH1A1 | |
| SCHEMBL17085864 | 0.75 | DPP4 (0.43) | MAPTALDH1A1 | |
| SCHEMBL14395686 | 0.74 | CALM1 (0.39) | ALDH1A1 | |
| SCHEMBL468178 | 0.73 | GPR84 (0.43) | GPR84ATP4AATP4BHSD11B1SOAT1 | |
| SCHEMBL11994177 | 0.72 | ATP4A (0.58) | ATP4AATP4BMAPTALDH1A1NPSR1 | |
| SCHEMBL11994165 | 0.72 | ALDH1A1 (0.47) | GPR84ATP4AATP4BMAPTALDH1A1 | |
| SCHEMBL10475629 | 0.71 | ALDH1A1 (0.71) | GPR84ATP4AATP4BMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120214798-A1 | Novel Ethanediamone Hepcidine Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214798-A1 | Novel Ethanediamone Hepcidine Antagonists | HAMP, SLC40A1, FTH1 | GPR84 623/4885ATP4A 2125/4885ATP4B 2231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.